The education of neurologists on the syndrome of juvenile myoclonic epilepsy (JME) has been one of the major successes in the treatment of epilepsy. For a long time, the original author to whom this condition is eponymously linked, as well as other experts, conceived of JME as a lifelong condition in which seizure relapse upon drug discontinuation is invariable. This report by Senf et al. on a group of 66 patients with JME followed for a mean of 44.6 years gives a reappraisal of several aspects of the condition.
The education of neurologists on the syndrome of juvenile myoclonic epilepsy (JME) has been one of the major successes in the treatment of epilepsy. For a long time, the original author to whom this condition is eponymously linked, as well as other experts, conceived of JME as a lifelong condition in which seizure relapse upon drug discontinuation is invariable. This report by Senf et al. on a group of 66 patients with JME followed for a mean of 44.6 years gives a reappraisal of several aspects of the condition. 1 Treatment response and long-term remission are more favorable than previously thought possible. Fifty-nine percent of patients attained 5-year terminal remission, with 16.6% of the cohort no longer taking antiepileptic medication. Other recent long-term outcome studies on JME report even slightly higher chances of being seizure free off medications (19%-26% of patients followed for 20 years or longer).
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Even in those not completely seizure free, there were only sporadic seizures with many years of seizure freedom in between.
The other face of JME is that a proportion remains resistant to treatment despite the advent of more and newer drugs. Predictors of seizure persistence have been hard to come by. Surprisingly, no consistent EEG variables can be identified. This study found the coexistence of absence seizures to be a predictor of disease persistence. When dealing with refractory JME, it may be well to remember the possible contribution of older therapies such as primidone, acetazolamide, and clonazepam. This study found primidone to be particularly efficacious when compared to valproate. Observation bias is possible, as this cohort was assembled at a time when only older drugs were available, and those who were responders then stayed on the same treatment.
